What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
1 Co-sponsor
3 Multi-sponsors
History
- Recommitted to higher education
- Returned to senate
- Repassed assembly
- Amended on third reading 544b
- Amended on third reading (t) 544a
- Vote reconsidered - restored to third reading
- Returned to assembly
- Recalled from senate
- Referred to higher education
- Delivered to senate
- Passed assembly
- Ordered to third reading cal.42
Show 9 earlier actions
- Returned to assembly
- Died in senate
- Referred to health
- Delivered to senate
- Passed assembly
- Advanced to third reading cal.349
- Reported
- Reported referred to codes
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Restricts retail sale of ipecac syrup to behind the pharmacy counter or under manager control
In Senate Committee · Higher Education · Sponsor Thomas K. Duane
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
BILL NUMBER:A544B
Title of bill
An act to amend the general business law, in relation to restricting access to ipecac syrup
Purpose or general idea of bill
To restrict the access to retail sale of ipecac.
Summary of specific provisions
Section 1 amends the general business law by adding a new section 391-q which restricts the access to retail sale of ipecac.
Justification
Ipecac syrup has long been distributed for emergency use to induce vomiting in poisoning cases. Recent years have seen an increase in ipecac abuse among sufferers of bulimia, anorexia and binge eating disorder. While ipecac is often effective in inducing emesis and decreasing the absorption of poisonous toxins, its side effects and abuse potential offer cause for concern.
Repeated use and abuse of ipecac syrup has been linked to skin condi- tions, cardiac and skeletal muscle weakness, and electrolyte imbalance, with sometimes fatal results. An emerging consensus among many profes- sional medical groups is that syrup of ipecac should no longer be used routinely as a poison treatment in the home. U.S.A. poison centers have also markedly reduced their use of ipecac syrup over the previous decade and, on June 12, 2003, the Food and Drug Administration's Nonprescrip- tion Drugs Advisory Committee recommended by a vote of six to four that the FDA rescind ipecac's over-the-counter status.
This legislation seeks to regulate the availability of, and access to, this noxious powerful emetic.
Prior legislative history
05/06/09 passed Assembly 02/01/10 passed Assembly
Fiscal implications
None to the State.
Effective date
This act shall take effect immediately; provided, however, that the rules and regulations necessary to implement section one of this act shall be promulgated and take effect on or before the one hundred eightieth day after this act shall have become law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.